Skip to content
Menu

Reported Sunday, Abbott’s TECTONIC Trial Of Investigational SonicForce Coronary IVL System Meets Primary Safety And Effectiveness Endpoints, With 0.3% 30-Day Target Lesion Failure And 97% Procedural Success In 335 Patient

Benzinga Newsdesk 2 weeks ago

News

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

  • SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary arteries and restore blood flow
  • The system is designed to bring purposeful innovation to treating complex coronary calcium, with longer treatment lengths, more pulses and enhanced catheter deliverability
  • Approval of the investigational system would further strengthen Abbott's comprehensive coronary devices portfolio, complementing its advanced imaging, lesion preparation and stent technologies

Read at benzinga.com

← All stock news